Notably, when using the i.p. route of injection, anti-PD-1 plus anti-Nrp-1 combination had similar effects on tumour progression than anti-PD-1 plus anti-CTLA-4 (Supplementary Fig. 6e). The gene discussed is CTLA4; the disease is neoplasm.